Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis

This is the author's manuscript

Original Citation:

Availability:
This version is available http://hdl.handle.net/2318/1666707 since 2019-08-01T16:10:28Z

Published version:
DOI:10.1080/00365521.2018.1459824

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Performance of PIVKA-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis

Gian Paolo Caviglia\textsuperscript{a}, Davide Giuseppe Ribaldone\textsuperscript{a}, Maria Lorena Abate\textsuperscript{a}, Alessia Ciancio\textsuperscript{a}, Rinaldo Pellicano\textsuperscript{b}, Antonina Smedile\textsuperscript{a} and Giorgio Maria Saracco\textsuperscript{a}

\textsuperscript{a}Department of Medical Sciences, University of Turin, Turin, Italy; \textsuperscript{b}Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy

Gian Paolo Caviglia, ORCID ID: 0000-0002-0529-9481, Department of Medical Sciences University of Turin, Turin, 10100, Italy. +39 11 633 3922. caviglia.giampi@libero.it

Davide Giuseppe Ribaldone, ORCID ID: 0000-0002-9421-3087, Department of Medical Sciences, University of Turin, Turin, 10100, Italy. +39 11 633 3902. davrib_1998@yahoo.com

Maria Lorena Abate, ORCID ID: 0000-0002-7611-6099, Department of Medical Sciences, University of Turin, Turin, 10100, Italy. +39 11 633 3629. marialorena.abate@unito.it

Alessia Ciancio, ORCID ID: 0000-0003-4188-0609, Department of Medical Sciences, University of Turin, Turin, 10100, Italy. +39 11 633 6224. alessiaciancio@libero.it

Rinaldo Pellicano, ORCID ID: 0000-0003-3438-0649, Unit of Gastroenterology and Hepatology, Città della Salute e della Scienza, Molinette Hospital, Turin, 10100, Italy. +39 11 633 3913. rinaldo_pellican@hotmail.com
Antonina Smedile, ORCID ID: 0000-0003-3438-0649, Department of Medical Sciences, University of Turin, Turin, 10100, Italy. +39 11 633 3913. antonina.smedile@unito.it

Giorgio Maria Saracco, ORCID ID: 0000-0001-5310-4143, Department of Medical Sciences, University of Turin, Turin, 10100, Italy. +39 11 633 6397. Giorgiomaria.saracco@unito.it

CONTACT Gian Paolo Caviglia, caviglia.giampi@libero.it, Department of Medical Sciences, University of Turin, Turin 10100, Italy.

Running title: PIVKA-II and HCC

Manuscript word count: 3384
ABSTRACT

Objectives: In the setting of surveillance for hepatocellular carcinoma (HCC) detection, the use of serum biomarkers in addition to ultrasonography (US) is still a matter of debate. Hence, we performed a meta-analysis to evaluate the diagnostic accuracy of protein induced by vitamin k absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) alone or in combination for HCC detection in patients at risk of tumor development.

Materials and methods: We performed a systematic search in PubMed and Scopus database for original articles published in English from 2011 to 2017, investigating the accuracy of PIVKA-II versus AFP (reported as area under the curve [AUC]) for HCC detection among patients at risk of tumor development. Furthermore, we focused on studies in which serum PIVKA-II was assessed by highly sensitive chemiluminescence immunoassay (CLEIA).

Results: A total of 10 studies (818 patients with HCC and 1136 patients with advanced liver disease/cirrhosis) were included in the meta-analysis. The weighted summary (s)AUC of PIVKA-II and AFP for the discrimination between patients with HCC and those without was 0.776 (0.732-0.820) and 0.763 (0.723-0.803), respectively. The combination of PIVKA-II + AFP results in a sAUC of 0.860 (0.836-0.883). The performance for HCC detection of PIVKA-II + AFP was significantly superior to each biomarker used alone (ΔsAUC = 0.084, p = 0.001 and ΔsAUC = 0.097, p < 0.001, respectively).

Conclusions: In clinical practice, the use of PIVKA-II + AFP in addition to US examination may improve the effectiveness of surveillance among patients at risk for HCC development.

KEYWORDS: alpha-fetoprotein; hepatocellular carcinoma; protein induced by vitamin k absence or antagonist II; surveillance; meta-analysis
**Introduction**

Despite the availability of direct-acting antiviral agents (DAAs) and potent nucleos(t)ide analogues (NAs) with high genetic barrier to resistance for treatment of patients with chronic hepatitis C and B, respectively, the prognosis of patients with advanced liver disease/cirrhosis responder to antiviral treatment is still characterized by a significant risk of hepatocellular carcinoma (HCC) development.[1,2]

Currently, surveillance programs for HCC detection in high risk population are mainly based on abdominal ultrasonography (US).[3,4] However, US has no predictive power on HCC development. Indeed, hepatocarcinogenesis is a gradual process characterized by genetic and molecular alterations progressively accumulating within hepatocytes before the appearance of a neoplastic lesion detectable by imaging.[5] Thus, additional tools allowing early HCC detection or prediction are needed to complement US screening. Among traditional serum markers, alpha-fetoprotein (AFP) is the most used worldwide despite showing suboptimal performance for HCC detection.[6] Conversely, novel classes of biomarkers involved in epigenetic machinery such as microRNAs (miRNAs) showed promising results.[7,8] However, their use in clinical practice may be limited by the absence of a standardized analytical method and by a complex miRNA-messenger RNA interference network reflecting different genetic and epigenetic features, that in turn may significantly alter miRNAs expression.[9]

Protein induced by vitamin K absence or antagonist II (PIVKA-II), also known as des-gamma-carboxy prothrombin, is a biomarker specific for HCC firstly described in 1984.[10] PIVKA-II is an hypo-carboxylated prothrombin released by the liver in absence of vitamin K or in presence of malignant cells; higher PIVKA-II serum levels are associated to tumor size, microvascular invasion and predict HCC recurrence.[11-13] The combination of PIVKA-II with AFP is currently used in Japan for surveillance of patients at risk of HCC development as recommended by the local HCC guidelines.[14] However, results regarding PIVKA-II performance in comparison or in combination with AFP are
conflicting and available data mainly derive from studies involving Asiatic patients;[15,16] results from Western studies are limited by the relatively small sample size. Furthermore, methods for PIVKA-II measurement in serum evolved over time from competitive radioimmunoassay and enzyme immunoassay to fully automated chemiluminescence enzyme immunoassay (CLEIA).[17] Thus, technical improvement may have affected analytical performance.

Considering the availability of novel CLEIA-based methods for PIVKA-II measurement and the lack of consensus regarding the usefulness of PIVKA-II in the setting of HCC surveillance, we performed a meta-analysis on the diagnostic accuracy of PIVKA-II alone or in combination with AFP for HCC detection among patients at risk of tumor development.

**Methods**

**Search strategy**

The meta-analysis of observational studies in epidemiology (MOOSE) reporting guidelines for the performance of meta-analyses have been followed.[18] Original research articles published in English on accuracy of PIVKA-II for the discrimination of patients with HCC from those with advanced liver disease/cirrhosis were identified through PubMed (https://www.ncbi.nlm.nih.gov/pubmed) and Scopus (https://www.scopus.com) database. The search strategy was based on the use of the following terms: “PIVKA-II” or “des-gamma-carboxy prothrombin” or “DCP” and “HCC” or “hepatocellular carcinoma”. Since we focused on articles in which PIVKA-II was tested by CLEIA method, only papers published from 1 Jan 2011, were screened. For both databases the search was performed on 30 August 2017. Patients with HCC were considered the “case group” whereas patients with advanced chronic liver disease or cirrhosis or with non-neoplastic liver nodules were considered as the “control group”. No restriction was set for age and sex of the patients.
**Study selection**

Two authors (GPC and DGR) independently reviewed the titles and the abstracts of the studies retrieved from electronic search and selected those potentially relevant for the meta-analysis. The full-text of selected studies was assessed by three authors (GPC, DGR and MLA) to determine whether the inclusion criteria were satisfied.

Inclusion criteria were: (1) original research articles published in English; (2) studies reporting PIVKA-II diagnostic accuracy for the discrimination between patients with HCC and patients with advanced liver disease/cirrhosis in comparison to AFP; and (3) studies investigating PIVKA-II performance assessed by CLEIA method. Duplicates studies and studies lacking of data of interest were excluded. The quality of included studies was assessed by the quality assessment of diagnostic accuracy studies (QUADAS) tool.[19] Accordingly, a maximum of 14 points could be awarded answering questions related to biases, variability and reporting.

**Data extraction**

From selected papers, the same two authors (GPC and DGR) extracted data regarding authors, Country, year of publication, number of patients, underlying liver disease etiology, biomarkers performance (area under the curve [AUC] and 95% confidence interval [CI]), sensitivity (Se) and specificity (Sp) at the corresponding cut-off value.

**Statistical analysis**

The meta-analysis was performed using MedCalc® software version 15.8.1 (Ostend, Belgium). Chi-square test was performed to evaluate difference of categorical variables between groups. Test for inter-rater agreement (Cohen Kappa statistics) was used to evaluate the agreement between investigators. The weighted summary (s)AUC was calculated including each AUC value and the
corresponding standard error (SE) from all included studies. SE was calculated with the following formula: \( SE = (\ln UB - \ln LB)/2 \times 1.96 \), where UB and LB were the upper and lower bound of the 95% CI of AUC, respectively.

Forrest plots showing the overall effect and funnel plots for publication bias assessment were constructed. According to the presence of heterogeneity, a fixed or random effects model was preferred. Cochran’s Q and I\(^2\) statistics were used to detect heterogeneity; a \( p \)-value < 0.1 and I\(^2\) value > 25% were considered as indicative of heterogeneity, respectively.

To measure funnel plot asymmetry, Egger regression analysis was performed.[20] Accordingly, the standard normal deviate, defined as the natural logarithm of estimate divided by its SE, was regressed against the estimate’s precision, defined as the inverse of the SE. The intercept of the regression line and the corresponding \( p \)-value provided the measure of asymmetry.

**Results**

A total of 10 studies were included in the meta-analysis (Table I).[21-30] The strategy search is depicted in Figure 1. There was no disagreement among authors regarding eligibility of original articles finally included in the meta-analysis (K statistics = 1.0). Overall, 1954 patients were included: 818 patients with HCC (Case group), 655 patients with cirrhosis and 481 with chronic liver disease (Control group). The underlying liver disease etiology was mainly viral, with a significant higher proportion of patients with chronic hepatitis B virus (HBV) infection (\( p < 0.001 \)).

The sAUC of PIVKA-II for the discrimination between patients with HCC and those without was 0.776 (0.732-0.820) (Figure 2). Since the studies showed heterogeneity \( p < 0.001 \) of Cohran’s Q and I\(^2\) = 71.3%), a random effects model was applied. The sAUC of AFP for the discrimination between patients with HCC and those without tumor was 0.763 (0.723-0.803) (Figure 3). Considering that the studies showed heterogeneity (\( p = 0.061 \) of Cohran’s Q and I\(^2\) = 44.7%), a random effects
model was applied. The sAUC of PIVKA-II in combination with AFP for the discrimination between patients with HCC and those without was 0.860 (0.836-0.883) (Figure 4). A fixed effects model was applied because the results of the studies showed no heterogeneity \((p = 0.578\) of Cohran’s Q and \(I^2 = 0\%\)). No differences were observed between PIVKA-II and AFP diagnostic accuracy \((\Delta sAUC = 0.013, p = 0.668)\), whereas the combination of PIVKA-II + AFP was significantly superior to each biomarker used alone \((\Delta sAUC = 0.084, p = 0.001\) and \(\Delta sAUC = 0.097, p < 0.001,\) respectively).

**Publication bias**

Egger test for publication bias showed that the risk of having missed or overlooked studies was minimal for the assessment of sAUC of PIVKA-II and AFP \((p = 0.035\) and \(p = 0.049,\) respectively), whereas no publication bias was observed for the analysis of biomarkers combination \((p = 0.583\) (Figure 5).

**Discussion**

The use of serum biomarkers for HCC surveillance is a matter of debate since no unequivocal evidence in improving early HCC detection has been produced.[31] Nevertheless, conventional biomarkers such as AFP and PIVKA-II are used in clinical practice, although not universally recommended by scientific guidelines.

AFP is the widest used biomarker in the setting of surveillance of high risk population albeit showing a large range of Se (40%-65%) and Sp (76%-96%) values for HCC detection.[32] Furthermore, AFP values are often increased in patients with chronic liver disease or cirrhosis and without HCC, as a consequence of inflammation, necrosis and regeneration.[33] Nonetheless, as suggested by Asian Pacific Association for the Study of the Liver, AFP used in combination with US, may be useful to increase Se without decreasing Sp for tumor recognition.[34]
To date, several biomarkers have been proposed as potential alternative or diagnostic complement to AFP.[35-39] Amongst these, PIVKA-II has been extensively investigated either alone or in combination with AFP, but results concerning performance for HCC detection are conflicting.[40,41] In the present meta-analysis including 10 studies, we found no difference between AFP and PIVKA-II diagnostic accuracy for the discrimination between patients with HCC and those without, but the combination of both biomarkers led to a significant improvement in the performance of HCC detection. Consistently, several studies focused either on the combination of biomarkers or on the development of scores that include different classes of biomarkers and even demographical or clinical characteristics,[28,42-46] in order to improve reliability and performance for HCC detection. As a matter of fact, these strategies showed promising results. Furthermore, some of these scores seem able to accurately predict HCC development among high risk patients.[28,47]

Another major issue is represented by the method used for biomarker assessment. Most of novel biomarker proposed for HCC detection have been assessed by non-standardized methods, not allowing to reliably reproduce or compare results from different studies and thus, still far from any potential use in clinical practice.[48] For this reason, only biomarkers evaluated by highly sensitive standardized methods may be recommended.

The results of this meta-analysis may be limited by lack of pathological characterization of HCC cases. Since data regarding HCC classification (i.e. staging according to Barcelona Clinic Liver Cancer system) or nodules features (such as number, size and vascular invasion) were absent or not limited to very early/early tumor stages, we could not assess the performance of biomarkers for early HCC detection. Another potential limitation is represented by the presence of non-cirrhotic patients in control group, as cirrhosis is considered the principal risk factor for HCC development. However, we included studies that enrolled as controls only patients with advanced liver diseases/cirrhosis in order to
obtain a control group representative of the real population under surveillance for the risk of HCC development.

In conclusion, the results of this meta-analysis highlight the added value of PIVKA-II and AFP combination for HCC detection rather than a single biomarker used alone. In clinical practice, the use of this combination in addition to US examination may be considered to improve the effectiveness of surveillance of patients at risk for HCC development. Nonetheless, prospective multicenter studies including a large cohort of patients with advanced liver disease/cirrhosis are needed to evaluate PIVKA-II + AFP performance for tumor prediction, thus allowing the identification of patients at higher risk of HCC development.

**Declaration of interest statement**

All authors have nothing to disclose regarding the material discussed in the present manuscript.
References

[1] Caviglia GP, Abate ML, Pellicano R, et al. Chronic hepatitis B therapy: available drugs and treatment guidelines. Minerva Gastroenterol Dietol. 2015;61:61-70.

[2] Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents. Gastroenterology. 2017; In press.

[3] European Association For The Study Of The Liver, European Organization For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.

[4] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.

[5] Lombardi A, Grimaldi A, Zappavigna S, et al. Hepatocarcinoma: genetic and epigenetic features. Minerva Gastroenterol Dietol. 2017; In press.

[6] Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44:E11-25.

[7] Petrini E, Caviglia GP, Abate ML, et al. MicroRNAs in HBV-related hepatocellular carcinoma: functions and potential clinical applications. Panminerva Med. 2015;57:201-209.

[8] Jia H, Yu H, Liu Q. Single nucleotide polymorphisms of MIR-149 gene rs2292832 contributes to the risk of hepatocellular carcinoma, but not overall cancer: a meta-analysis. Minerva Med. 2016;107:259-269.

[9] Abenavoli L, Boccuto L. New serum markers for detection of early hepatocellular carcinoma. Panminerva Med 2017; In press.

[10] Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427-1431.
[11] Baek YH, Lee JH, Jang JS, et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology. 2009;56:763-767.

[12] Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma—with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235-240.

[13] Kim DY, Paik YH, Ahn SH, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology. 2007;72:52-57.

[14] Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685.

[15] Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282.

[16] Song PP, Xia JF, Inagaki Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22:262-274.

[17] Choi J, Park Y, Kim JH, et al. Evaluation of automated serum des-gamma-carboxyprothrombin (DCP) assays for detecting hepatocellular carcinoma. Clin Biochem. 2011;44:1464-1468.

[18] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.

[19] Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.
[20] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.

[21] Poté N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854.

[22] Yu R, Ding S, Tan W, et al. Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population. Hepat Mon. 2015;15:e28806.

[23] Viggiani V, Palombi S, Gennarini G, et al. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Scand J Gastroenterol. 2016;51:1257-1262.

[24] Sultanik P, Ginguay A, Vandame J, et al. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse® G600 analyzer. J Viral Hepat. 2017;24:80-85.

[25] Ji J, Wang H, Li Y, et al. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study. PLoS One. 2016;11:e0153227.

[26] Yu R, Xiang X, Tan Z, et al. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep. 2016;6:35050.

[27] Saitta C, Raffa G, Alibrandi A, et al. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore). 2017;96:e7266.

[28] Caviglia GP, Abate ML, Gaia S, et al. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Med. 2017; In press.
[29] Gentile I, Buonomo AR, Scotto R, et al. Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. In Vivo. 2017;31:695-700.

[30] Wang X, Zhang W, Liu Y, et al. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47.

[31] Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853.

[32] Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci. 2013;14:23559-23580.

[33] Tateishi R, Yoshida H, Matsuyama Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2:17-30.

[34] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370.

[35] Song PP, Xia JF, Inagaki Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22:262-274.

[36] El-Serag HB, Kanwal F, Davila JA, et al. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146:1249-1255.

[37] Lou J, Zhang L, Lv S, et al. Biomarkers for Hepatocellular Carcinoma. Biomark Cancer. 2017;9:1-9.
[38] Fouad YM, Mohamed HI, Kamal EM, et al. Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2016;51:1133-1137.

[39] Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353.

[40] Li C, Zhang Z, Zhang P, et al. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44:E11-25.

[41] Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006;101:2038-2043.

[42] Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23:144-153.

[43] Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res. 2016;46:E130-E135.

[44] Feier D, Lupisor Platon M, Stefanescu H, et al. Transient elastography for the detection of hepatocellular carcinoma in viral C liver cirrhosis. Is there something else than increased liver stiffness? J Gastrointestin Liver Dis. 2013;22:283-289.

[45] Attallah AM, Omran MM, Attallah AA, et al. HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Br J Cancer. 2013;109:1657-1665.
[46] El-mezayen HA, Darwish H. Development of a novel score for early detection of hepatocellular carcinoma among high-risk hepatitis C virus patients. Tumour Biol. 2014;35:6501-6509.

[47] Berhane S, Johnson PJ, Tada T, et al. Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology. J Hepatol. 2017;66:S628.

[48] Schütte K, Schulz C, Link A, et al. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7:139-149.
Table 1. Studies included in meta-analysis.

| Study                  | Country | Year of publication | No. of patients | Etiology                          | Quality (QUADAS) |
|------------------------|---------|---------------------|-----------------|-----------------------------------|------------------|
| Potè et al. [21]       | France  | 2015                | HCC = 85        | 32 HCV / 17 HBV / 36 n.a.        | 13               |
|                        |         |                     | LC = 43         | 30 HCV / 13 HBV                   |                  |
| Yu et al. [22]         | China   | 2015                | HCC = 134       | 121 HBV / 3 HCV / 10 non-viral    | 11               |
|                        |         |                     | LC = 100        | 100 HBV                           |                  |
|                        |         |                     | CLD = 247       | 247 HBV                           |                  |
| Viggiani et al. [23]   | Italy   | 2016                | HCC = 60        | 60 n.a.                           | 7                |
|                        |         |                     | CLD = 60        | HCV / HBV / SOL (number n.a.)     |                  |
| Sultanik et al. [24]   | France  | 2016                | HCC = 46        | 26 HCV / 13 HBV / 7 HCV + HBV    | 13               |
|                        |         |                     | LC = 116        | 113 HCV / 2 HBV / 1 HCV + HBV    |                  |
| Ji et al. [25]*        | China   | 2016                | HCC = 200       | 200 HBV                           | 11               |
|                        |         |                     | LC = 41         | 41 HBV                            |                  |
|                        |         |                     | CLD = 56        | 56 HBV                            |                  |
| Yu et al. [26]         | China   | 2016                | HCC = 51        | 51 HBV                            | 12               |
|                        |         |                     | LC = 101        | 101 HBV                           |                  |
| Study               | Country | Year | HCC Count | Virology Breakdown | LC Count | CLD Count |
|---------------------|---------|------|-----------|--------------------|----------|-----------|
| Saitta et al.[27]   | Italy   | 2017 | 40        | 31 viral / 9 non-viral | 50       | 27        |
|                     |         |      |           |                    |          |           |
|                     |         |      |           | 27 viral / 23 non-viral |          |           |
| Caviglia et al.[28] | Italy   | 2017 | 33        | 33 HBV             | 30       | 27        |
|                     |         |      |           |                    |          |           |
|                     |         |      |           | 30 HBV             |          |           |
| Gentile et al.[29]  | Italy   | 2017 | 56        | 56 HCV             | 72       | 32        |
|                     |         |      |           |                    |          |           |
|                     |         |      |           | 72 HCV             |          |           |
|                     |         |      |           |                    |          |           |
| Wang et al.[30]     | China   | 2017 | 113       | 113 HBV            | 102      | 59        |
|                     |         |      |           |                    |          |           |
|                     |         |      |           | 102 HBV            |          |           |

*Only cohort B (high risk population surveillance) was included in meta-analysis.

CLD: chronic liver disease; n.a.: not available; QUADAS: quality assessment of diagnostic accuracy studies; SOL: solid occupying lesion.
Table 2. Raw data of the studies included.

| Study          | Biomarker  | AUC (95%CI)       | SE     | Cut-off      | Se   | Sp   |
|----------------|------------|-------------------|--------|--------------|-----|------|
| Potè et al. [21] | PIVKA-II   | 0.810 (0.697 - 0.924) | 0.072  | 42 mAU/mL   | 77% | 82%  |
|                | AFP        | 0.582 (0.443 - 0.722) | 0.125  | 5.5 ng/mL   | 61% | 50%  |
|                | PIVKA-II + AFP | 0.826 (0.722 - 0.929) | 0.064  | /            | /   | /    |
| Yu et al. [22]  | PIVKA-II   | 0.760 (0.699 - 0.820) | 0.041  | 200 mAU/mL   | 64.2% | 90.8% |
|                | AFP        | 0.826 (0.784 - 0.869) | 0.026  | 192.2 ng/mL | 60.4% | 89.6% |
|                | PIVKA-II + AFP | 0.846 (0.804 - 0.888) | 0.025  | a or b      | 73.1% | 83.3% |
| Viggiani et al.[23] | PIVKA-II | 0.814 (0.735 - 0.890) | 0.049  | 47 mAU/mL   | 60% | 90%  |
|                | AFP        | 0.618 (0.516 - 0.720) | 0.085  | 20 ng/mL    | 55% | 55%  |
|                | PIVKA-II + AFP | n.a.               | /      | /            | 75% | 61%  |
| Sultanik et al.[24]  | PIVKA-II   | 0.890 (0.820 - 0.960) | 0.040  | 128 mAU/mL   | 74% | 92%  |
|                | AFP        | 0.770 (0.680 - 0.860) | 0.060  | 20 ng/mL    | 63% | 82%  |
|                | PIVKA-II + AFP | 0.900 (0.840 - 0.960) | 0.034  | a or b      | 87% | 76%  |
| Ji et al.[25]* | PIVKA-II   | 0.913 (0.884 - 0.941) | 0.016  | 40 mAU/mL   | 82.6% | 90.7% |
|                | AFP        | 0.691 (0.638 - 0.743) | 0.039  | 20 ng/mL    | 62.0% | 69.1% |
|                | PIVKA-II + AFP | 0.840 (0.796 - 0.885) | 0.027  | /            | 78.5% | 93.8% |
| Study                  | PIVKA-II   | AFP          | PIVKA-II + AFP | 32 mAU/mL  | 5.0 ng/mL | 60 mAU/mL  | 60%         | 88%         | 60%         | 88%         | 58.3%     | 92.6%     |
|-----------------------|------------|--------------|---------------|------------|-----------|------------|--------------|--------------|--------------|--------------|------------|------------|
| Yu et al.[26]         | 0.718 (0.619 - 0.818) | 0.071 | 32 mAU/mL<sup>a</sup> | 58.3% | 92.6% | 75.0% | 91.7% | 88.9% | 85.2% |
|                       | 0.829 (0.749 - 0.909) | 0.049 | 5.0 ng/mL<sup>b</sup> |            |           |          |            |            |            |            |           |           |
|                       | 0.886 (0.826 - 0.945) | 0.034 |             |            |           |          |            |            |            |            | a or<sup>b</sup> |           |
| Saitta et al.[27]     | 0.710 (0.596 - 0.823) | 0.082 | 60 mAU/mL   | 60% | 88% | 67% | 68% | 70% | 94% |
|                       | 0.718 (0.613 - 0.823) | 0.075 | 6.5 ng/mL   |          |           |          |            |            |            |            |           |           |
|                       | 0.764 (0.665 - 0.862) | 0.066 |             |            |           |          |            |            |            |            | 70% | 94% |
| Caviglia et al.[28]   | 0.846 (0.734 - 0.924) | 0.059 | 58 mAU/mL   | 91% | 71% |            |          |            |            |            |            |           |           |
|                       | 0.791 (0.671 - 0.882) | 0.070 | 9.5 ng/mL   |          |           |          |            |            |            |            | 61% | 87% |
|                       | 0.890 (0.786 - 0.954) | 0.050 |             |            |           |          |            |            |            |            | 91% | 77% |
| Gentile et al.[29]    | 0.788 (0.707 - 0.868) | 0.052 | 36 mAU/mL<sup>a</sup> | 78.6% | 66.3% |            |          |            |            |            |            | 78.6% | 66.3% |
|                       | 0.756 (0.676 - 0.836) | 0.054 | 12 ng/mL<sup>b</sup> | 60.0% | 77.2% |            |          |            |            |            |            |           |           |
|                       | /           | /           | /           | a and<sup>b</sup> | 92.5% | 51.4% |            |          |            |            |            |           |           |
| Wang et al.[30]       | 0.756 (0.698 - 0.814) | 0.039 | 32.6 mAU/mL | 52.2% | 81.5% |            |          |            |            |            |            |           |           |
|                       | 0.781 (0.726-0.836) | 0.036 | 17.6 ng/mL | 64.6% | 73.3% |            |          |            |            |            |            |           |           |
|                       | 0.868 (0.822-0.913) | 0.027 | 50.23 | 74.3% | 89.4% |            |          |            |            |            |            |           |           |

*Only cohort B (high risk population surveillance) was included in meta-analysis.

AFP, alpha-fetoprotein; AUC, area under the curve; CI, confidence interval; n.a.; not available; PIVKA-II, protein induced by vitamin absence or antagonist II; Se, sensitivity; SE, standard error; Sp, specificity.
Figure 1. Study screening and selection.

PIVKA-II: protein induced by vitamin k absence or antagonist II.
Figure 2. Forrest plot (A) and funnel plot (B) of PIVKA-II accuracy for HCC detection.

AUC: area under the curve; PIVKA-II: protein induced by vitamin k absence or antagonist II.
Figure 3. Forrest plot (A) and funnel plot (B) of AFP accuracy for HCC detection.

AFP: alpha-fetoprotein; AUC: area under the curve.
Figure 4. Forrest plot (A) and funnel plot (B) of PIVKA-II + AFP accuracy for HCC detection.

AFP: alpha-fetoprotein; AUC: area under the curve; PIVKA-II: protein induced by vitamin k absence or antagonist II.
Figure 5. Egger regression plot of PIVKA-II (A), AFP (B) and PIVKA-II + AFP (C).

AFP: alpha-fetoprotein; AUC: area under the curve; ln: natural logarithm; PIVKA-II: protein induced by vitamin k absence or antagonist II; SE: standard error.